Modular Medical

MODD

Market cap $41.5M

Overview Fund Activity

0.7500 USD

+0.0498

7.11%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

0.7354

-0.0146

1.95%

1 day

7.11%

5 days

3.45%

1 month

4.75%

3 months

-5.9%

6 months

-13.8%

Year to date

-46.81%

1 year

-65.75%

5 years

-79.78%

10 years

-79.78%

About: Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

Employees: 54

Healthcare Medical Devices

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

13% more funds holding

Funds holding: 32 [Q1] → 36 (+4) [Q2]

8.78% less ownership

Funds ownership: 41.19% [Q1] → 32.41% (-8.78%) [Q2]

28% less capital invested

Capital invested by funds: $18.2M [Q1] → $13.1M (-$5.15M) [Q2]

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

See Fund Rankings

Financial journalist opinion

Modular Medical Announces Completion of Clinical Study of MODD1 Pump

- Use of MODD1 on clinicians with Type 1 diabetes SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target the estimated $3 billion dollar adult "almost-pumpers" market with its user-friendly and affordable design, today announced the successful completion of a clinical study with the MODD1 pump. The MODD1 was worn by nine clinicians with Type 1diabetes who currently wear a continuous glucose monitor ("CGM") and other pumps to provide the Company with real-world experience and feedback to make further refinements for the launch of its next-generation Pivot pump product.

Modular Medical Announces Completion of Clinical Study of MODD1 Pump

Modular Medical Announces Completion of MODD1 Cartridge Production and Commencement of Pivot Conversion

-More than 6,000 MODD1 cartridges produced - Conversion to Pivot-ready manufacturing in preparation for product launch in 1Q26 SAN DIEGO, CA / ACCESS Newswire / August 26, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that the MODD1 product cartridge production run has been completed and its manufacturing line is being converted to production for its Pivot product. "I want to congratulate our operational team for the successful validation of our MODD1 manufacturing process and production of human use cartridges," said Jeb Besser, CEO of Modular Medical.

Modular Medical Announces Completion of MODD1 Cartridge Production and Commencement of Pivot Conversion

Modular Medical Announces Next-Generation Pivot Insulin Pump at ADCES and Introduction of Level Ex Gamified Training Collaboration

-Debuting a "coming soon" campaign for tubeless Pivot patch pump - Expects special 510(k) filing for Pivot product in October - Will introduce first level of its gamified training application developed by Level Ex, developers of the Level One diabetes-management game SAN DIEGO, CA / ACCESS Newswire / August 8, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced its participation at the Association of Diabetes Care & Education Specialists ("ADCES") Conference, which is being held in Phoenix, Arizona from August 8 to August 11, 2025. With over 11,000 members, the ADCES is a national network of diabetes care and education specialists working to optimize clinical outcomes for people with diabetes.

Modular Medical Announces Next-Generation Pivot Insulin Pump at ADCES and Introduction of Level Ex Gamified Training Collaboration

Modular Medical Announces First Human Use of MODD1 Pump Delivering Insulin

- Use of MODD1 on clinician with Type 1 diabetes - Modular Medical intends to deploy the MODD1 on a larger number of clinicians in mid August SAN DIEGO, CA / ACCESS Newswire / August 6, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target the estimated $3 billion dollar adult "almost-pumpers" market with its user-friendly and affordable design, today announced the first human use of the MODD1 pump to deliver insulin to a person with diabetes in a real-world setting. The MODD1 is delivering insulin to a clinician with Type 1 under institutional review board approval from the United States Food and Drug Administration, which is necessary because the reusable controller line is being validated for human use.

Modular Medical Announces First Human Use of MODD1 Pump Delivering Insulin

Modular Medical Announces MODD1 Cartridge Line Validated for Human-Use Production

-Line has been in production at risk since early July - Production to continue until late August when conversion to Pivot manufacturing will begin SAN DIEGO, CA / ACCESS Newswire / August 4, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, announced that the MODD1 cartridge line has been validated for human-use production in the United States. "This is an important milestone for scaling up our manufacturing infrastructure to support our commercial pilot for MODD1 and, eventually, our 3ml Pivot tubeless patch pump launch," stated Jeb Besser, CEO of Modular Medical.

Modular Medical Announces MODD1 Cartridge Line Validated for Human-Use Production

24/7 Wall Street

Insiders Invested Millions in these Five Rebounding Stocks

Marriott Vacations Worldwide director Christian Asmar bought 412,449 shares for just over $27.88 million.

Insiders Invested Millions in these Five Rebounding Stocks

Modular Medical to Present Data from Study Examining Pump Delivery of a GLP-1R Agonist at the ADA 85th Scientific Sessions

SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, is pleased to announce its participation in the American Diabetes Association ("ADA") 85th Scientific Sessions, taking place June 20-23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. The Company will feature a poster, number 783-P, titled "Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse," to be presented by David Maggs, MD, FRCP during the General Poster Session on Sunday, June 22, 2025, from 12:30pm to 1:30pm in the Poster Hall.

Modular Medical to Present Data from Study Examining Pump Delivery of a GLP-1R Agonist at the ADA 85th Scientific Sessions

Modular Medical Appoints Industry Veteran Jeff Goldberg to Board of Directors

SAN DIEGO, CA / ACCESS Newswire / May 28, 2025 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, today announced the appointment of Jeff Goldberg to its Board of Directors. Mr. Goldberg brings decades of experience in health care, life sciences, and medical device leadership, including development of generic insulin.

Modular Medical Appoints Industry Veteran Jeff Goldberg to Board of Directors

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event Titled "Making Diabetes Management Simpler: The New Era of Insulin Therapy" Featuring Modular Medical CEO - Wednesday, May 28, 2025

Meet with Modular Medical CEO Jeb Besser There are 1.9 million individuals with Type 1 Diabetes in the US. 100% of patient population require daily insulin injection.

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event Titled "Making Diabetes Management Simpler: The New Era of Insulin Therapy" Featuring Modular Medical CEO - Wednesday, May 28, 2025

Modular Medical to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

SAN DIEGO, CA / ACCESS Newswire / May 22, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually, on Thursday, May 29, 2025. Company Webcast The webcast presentation will take place at 11:00 a.m.

Modular Medical to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

See News Rankings

Charts implemented using Lightweight Charts™